GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Inventory Turnover

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Inventory Turnover : 0.07 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Chongqing Genrix Biopharmaceutical Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥3.44 Mil. Chongqing Genrix Biopharmaceutical Co's Average Total Inventories for the quarter that ended in Mar. 2025 was ¥51.56 Mil. Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.07.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Mar. 2025 was 1,366.99.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 2.56.


Chongqing Genrix Biopharmaceutical Co Inventory Turnover Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Inventory Turnover Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory Turnover
Get a 7-Day Free Trial 0.06 0.78 0.01 0.01 0.10

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.04 0.05 0.07

Chongqing Genrix Biopharmaceutical Co Inventory Turnover Calculation

Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Inventory Turnover (A: Dec. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2024 ) / ((Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count )
=5.31 / ((55.451 + 50.149) / 2 )
=5.31 / 52.8
=0.10

Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover (Q: Mar. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2025 ) / ((Total Inventories (Q: Dec. 2024 ) + Total Inventories (Q: Mar. 2025 )) / count )
=3.442 / ((50.149 + 52.978) / 2 )
=3.442 / 51.5635
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2025 )/Cost of Goods Sold (Q: Mar. 2025 )*Days in Period
=51.5635/3.442*365 / 4
=1,366.99

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chongqing Genrix Biopharmaceutical Co's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=51.5635 / 20.156
=2.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Chongqing Genrix Biopharmaceutical Co Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines